CARL ZEISS MEDITEC AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.08 EUR | +2.16% |
|
+2.66% | -2.24% |
| 10/05 | CARL ZEISS MEDITEC AG : Hauck & Aufhauser gives a Buy rating | ZD |
| 09/05 | CARL ZEISS MEDITEC AG : Deutsche Bank sticks Neutral | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Sales forecast by analysts have been recently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 33.93 and 26.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.07 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.24% | 9.31B | - | ||
| +12.06% | 227B | B | ||
| +12.07% | 192B | B- | ||
| +13.88% | 136B | B- | ||
| +27.12% | 108B | A- | ||
| +0.72% | 64.07B | A- | ||
| +13.39% | 52.1B | B+ | ||
| +6.74% | 51.87B | B+ | ||
| +8.81% | 44.33B | A | ||
| +4.14% | 36.75B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AFX Stock
- 0DHC Stock
- Ratings Carl Zeiss Meditec AG